PRQR
HOLD / NEUTRALMeanRevComposite
45.50
Technical
86.30
Fundamental
31.90
Rank
—
Price
2.27
Hurst
0.20
As of
Aug 21, 2026
Daily
ProQR Therapeutics N.V.
HealthcareBiotechnologyProQR Therapeutics N.V. is a clinical-stage biotech company developing RNA editing treatments for genetic disorders using its Axiomer platform technology. The company's pipeline includes candidates targeting cholestatic diseases, Rett syndrome, metabolic liver disease, and cardiovascular conditions, with a research partnership with Eli Lilly focused on liver and nervous system disorders. Founded in 2012 and based in the Netherlands, ProQR aims to address genetic diseases with limited existing treatment options.
Market cap
$196.2M
P/E (trailing)
—
P/E (forward)
-3.00
PEG ratio
—
Dividend yield
0.00%
Beta
0.20
52w range
1.20 – 2.81
Return on equity
-57.40%
Profit margin
-228.18%
Revenue growth
+120.40%
Earnings growth
—
Price history
1Y: 1.39 (-49.5%) · range 1.24–2.75
Cycle position
3/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 86 · STRONG SETUP · exit proximity 0
Conviction
47/ 100 · maturity 0%
Buildup.3310
EMA entry setup.4286
Fundamentals.2532
Volume profile
POC
1.69
Price vs POC
-17.8%
Overhead supply
92%
Runway
+12.6%
Value area 1.43–1.93 · 92% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -20.51% | +3.85% | mature |
| 40d | -44.02% | +3.85% | mature |